VIR News and Press, Vir Biotechnology Inc. From 06/05/24

2024-06-05 08:46:27 ET Read the full article on Seeking Alpha For further details see: Vir gains on early mid-stage data for hepatitis candidate

– Preliminary Phase 2 SOLSTICE trial data reinforce the potential of both regimens to be transformative treatments in an area of high unmet medical need – – Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST – Vir Biotechnol...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference on Wednesday, June 12, at 11:00 a.m. PT / 2:00 p.m. ET at the...

2024-05-29 08:20:28 ET More on Vir Biotechnology Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders Vir Biotechnology GAAP EPS of -$0.48 beats by $0.59, revenue of $56.38M beats by $44.67M Read the full article on Seeking Alpha For further ...

– Exceptional biotech executive brings more than 32 years of leadership to Vir – – Deep knowledge in immunology and infectious disease with proven track record of bringing late-stage clinical development candidates into market – Vir Biotechnology,...

Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast. Vir Biotechnology’s stockholders of rec...

– Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial – – Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST – Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstra...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Associ...

2024-05-03 12:47:06 ET Summary Vir Biotechnology, Inc. reported its first-quarter earnings after the bell on Thursday, giving its shareholders some positive tidbits. The company continues to have a cash balance higher than the stock's market capitalization and has some potential u...

2024-05-03 00:35:24 ET Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Conference Call May 02, 2024, 04:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Carri...